• Quarterly sales rose by 80% compared to the corresponding quarter in FY25
• NervAlign® Nerve Cuff approved for use in US Department of Defence (DoD) and Veterans Affairs hospital network
• Empliq product ranges launched with first sale of the Empliq dermal

During the quarter, ReNerve continued to build commercial momentum, with sales for the quarter increasing by 80% relative to the corresponding period in FY25. With an increase in surgeon use, clinical trial validation, the launch of the Empliq product ranges and approvals that allow simplified purchasing in DoD and VA healthcare centres, ReNerve is confident in the strong foundation for future sales growth. The Company also launched its Empliq human tissue product ranges and achieved the first sale of the Empliq dermal along with first sale of the amniotic tissue products occurring in October. ReNerve continues to focus on sales expansion through the US market, and with 21 US distribution partners, ongoing surgeon engagement and hospital approvals, the Company anticipates strong growth over the coming years as the market adopts its products. The Company continues to pursue the significant global opportunity for PNI repair products, with plans to focus on approval for the NervAlign® Nerve Cuff in India, European approval submission, and market launch of the 1st NervAlign® Nerve Conduit in 1H CY2026.

Sales for the quarter totalled A$97k, representing an 80% increase compared to the corresponding quarter in the prior year. The Company completed Tranche 1 of its capital raise, receiving $2.6m in financing inflows of its $3.2m secured.

ReNerve continues to focus on sales expansion through the US market, and with 21 US distribution partners, ongoing surgeon engagement and hospital approvals, the Company anticipates strong growth over the coming years as the market adopts its products. This will be enhanced by additional products within the portfolio that provide surgeons and medical practitioners with a full suite of PNI repair treatments.